Portfolio News
Sofinnova Industrial Biotech
DMC Biotechnologies Appoints Industry Veteran K’Lynne Johnson as Chair of the Board
Related Company
DMC BiotechnologiesRelated Strategy
Industrial BiotechRelated Deal lead
Joško BobanovićBoulder, CO — May 19, 2025 — DMC Biotechnologies (DMC), a biomanufacturing company transforming chemical production through precision fermentation, today announced the appointment of K’Lynne Johnson as Chair of the Board of Directors. Johnson brings more than 25 years of global leadership in both high-growth technology ventures and established chemical companies.
Her appointment comes as DMC enters a critical phase of commercial expansion and launches its Series C fundraising round to support full-scale production and sales growth of its first products.
“K’Lynne’s track record in scaling breakthrough technologies and shaping strategy across both startups and global enterprises makes her an ideal leader for our board,” said Jim Flatt, CEO of DMC. “Her guidance will be pivotal as we commercialize products from our biomanufacturing technology platform, expand our customer base, and deliver sustainable solutions at scale.”
Johnson was the founding CEO of Elevance Renewable Sciences, a specialty chemicals company leveraging renewable feedstock. She also held senior leadership roles at Innovene, BP, and Amoco Corporation. In addition to her new role at DMC, Johnson currently serves on the boards of FMC Corporation, Trinseo Corporation, JM Huber Corporation, and BlueScope Steel Limited.
“DMC has built a powerful technology platform with real commercial momentum,” said Johnson. “I’m excited to help the team bring sustainable, scalable alternatives to market and drive meaningful change in the chemical industry.”
DMC’s Series C round will fuel market launches and sales growth of DMC’s first products in the nutrition, personal care and bio-based materials industries, expanding its customer base and chemicals partnerships, and supporting the company in scaling product manufacture.
To learn more about DMC Biotechnologies and its commitment to sustainable, high-performance ingredients, visit www.dmcbio.com.
Media Contact:
media@dmcbio.com
About DMC
DMC is a U.S.-based biomanufacturer redefining how the world produces chemicals. Through precision fermentation and synthetic biology, DMC creates sustainable, bio-based alternatives that reduce carbon emissions, enhance ingredient quality, and strengthen global supply chain resilience. The company’s proprietary platform, Dynamic Metabolic Control™, simplifies biological processes to enable predictable, scalable, and highly efficient fermentation—unlocking a new era of low-impact chemical manufacturing.
Related News
Sitryx regains rights to SYX-1042 itaconate mimetic for chronic autoimmune and inflammatory diseases from Lilly following portfolio reprioritization
Bioptimus Strengthens Commercial and Scientific Leadership with Key Hires
Pi-Cardia’s ShortCut™ becomes First Leaflet Modification Technology to receive CMS NTAP for Valve-in-Valve TAVR
Purespring Therapeutics receives UK CTA approval for Phase I/II clinical trial of PS-002 in patients with primary IgA nephropathy (IgAN)
Nuage Therapeutics welcomes Olivier Corminboeuf and Blandine Guimet to Leadership Team